Methods of treating infections caused by free-living amoeba are disclosed. The methods generally include systemic administration of an effective amount of miltefosine, such as an oral or intravenous formulation, and optionally local administration of an effective amount of miltefosine, such as a topical formulation of miltefosine. The methods may further include administration of one or more secondary agents. Exemplary secondary agents include steroids, polyhexamethylene biguanide (PHMB), chlorhexidine, propamidine isethionate, dibromopropamidine isethionate, neomycin, paromomycin, polymyxin B, clotrimazole, ketoconazole, miconazole, and itraconazole. The methods may be used to treat patients with infections caused by a free-living amoeba such as Naegleria fowleri, Balamuthia mandrillaris, Sappinia diploidea, and Acanthamoeba species. Exemplary infections include Acanthamoeba keratitis, granulomatous amoebic encephalitis, cutaneous acanthamoebiasis, primary amoebic meningoencephalitis, Sappinia amoebic encephalitis, or a disseminated disease associated with a free-living amoeba.

Methods for treating eye diseases associated with inflammation and/or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.

The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention.

To provide novel pesticides, especially insecticides or acaricides. A condensed heterocyclic compound represented by the formula (1) or its salt, or N-oxide thereof: ##STR00001##
wherein Q is a structure represented by Q1, Q2 or the like, D substituted with S(O).sub.nR.sup.1 is a structure represented by D1 or D2, A.sup.1 is N(A.sup.1a) or the like, A.sup.1 a is C.sub.1-C.sub.6 alkyl or the like, A.sup.4 is a nitrogen atom or C(R.sup.4), A.sup.5 is a nitrogen atom or C(R.sup.6), R.sup.1 is C.sub.1-C.sub.6 alkyl or the like, each of R.sup.2, R.sup.5 and R.sup.6 is independently a hydrogen atom or C.sub.1-C.sub.6 alkyl, each of R.sup.3, R.sup.4, Y1, Y2, Y3 and Y4 is independently a halogen atom, halo (C.sub.1-C.sub.6) alkyl or the like, and n is an integer of 0, 1 or 2.

An anti-Acanthamoeba agent contains luliconazole crystal as an active ingredient. The luliconazole has a crystal habit in which a ratio of I (20-2) to a total sum of I (001), I (100), I (10-1), I (011), I (110), I (11-1), I (10-2), I (11-2), I (020), I (021), I (20-2), I (121), I (013), I (11-3), and I (221) is 12% or more and/or a ratio of I (10-2) to a total sum of I (001), I (100), I (10-1), I (011), I (110), I (11-1), I (10-2), I (11-2), I (020), I (021), I (20-2), I (121), I (013), I (11-3), and I (221) is 20% or more.

The present invention provides compositions which comprise an extract with at least 5% in weight of anthocyanins and an extract with at least 15% in weight of phenylpropanoids which are specially indicated for their use in weight reduction periods because they reduce appetite and increase satiety though digestive tract-secreted hormones level modification. In a parallel and complementary way, these compositions act on the lipid metabolism of the adipose tissue cells by activating AMPK sensors and the fat oxidative and elimination pathways. Said composition is obtained by hydro-alcoholic extraction of Rosella flowers and Lemon Verbena leafs, using in the case of Lemon Verbena alcohol concentrations (ethanol, methanol, propanol, isopropanol or butanol) greater than 70 and up to 100% in volume).

Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.

Described herein are methods of expressing nucleic acids in T cells pre-exposed to a co-stimulatory signal and then transduced with adenoviral vectors. In some embodiments, the co-stimulation is provided by anti-CD3 and anti-CD28 antibodies and the adenoviral vector is pseudotyped for T-cell entry. The invention also relates to compositions for carrying out these methods, provided as kits or pharmaceutical compositions that can be used to treat diseases including immunological conditions and hematological malignancies.

To provide novel pesticides, especially insecticides or acaricides.

A condensed heterocyclic compound represented by the formula (1) or its salt, or N-oxide thereof:

##STR00001##

wherein Q is a structure represented by Q1, Q2 or the like, D substituted with S(O).sub.nR.sup.1 is a structure represented by D1 or D2, A.sup.1 is N(A.sup.1a) or the like, A.sup.1a is C.sub.1-C.sub.6 alkyl or the like, A.sup.4 is a nitrogen atom or C(R.sup.4), A.sup.5 is a nitrogen atom or C(R.sup.5), R.sup.1 is C.sub.1-C.sub.6 alkyl or the like, each of R.sup.2, R.sup.5 and R.sup.6 is independently a hydrogen atom or C.sub.1-C.sub.6 alkyl, each of R.sup.3, R.sup.4, Y1, Y2, Y3 and Y4 is independently a halogen atom, halo (C.sub.1-C.sub.6) alkyl or the like, and n is an integer of 0, 1 or 2.

The present invention is intended to provide a novel parasiticide, antiprotozoal or other endoparasite control agents which are effective for controlling animal endoparasites that have been impossible to control by conventional ones. Provided is an endoparasite control agent comprising, as an active ingredient, a carboxamide derivative represented by the general formula (I): ##STR00001##
or a salt thereof.